Swedish cancer diagnostics company INIFY Laboratories AB (Euronext Growth Oslo:INIFY) announced on Wednesday that it is expanding its operations into the United Kingdom.
The company plans to invest approximately SEK150m to establish a new laboratory in the UK, aiming to address challenges in prostate cancer care.
The UK market for cancer diagnostics is estimated to be significantly larger than Sweden's, with around 120,000 patients annually requiring prostate cancer diagnosis. Inify believes its technology can improve response times and quality of care in the UK healthcare system.
Initial samples from the UK will be handled by Inify's Swedish laboratory during the establishment phase. The company expects the new UK laboratory to be operational in early 2026.
In addition to prostate cancer, Inify plans to offer diagnostics for gastrointestinal diseases, a market with a significantly larger volume of samples and a wider range of conditions.
(EUR1=SEK11.42)
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
GlycoMimetics to combine with Crescent Biopharma
MilliporeSigma expands ADC manufacturing capacity
Merck and Moderna launch new Phase 3 trial for cancer vaccine
RaySearch Laboratories AB names new CFO
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
Elicera Therapeutics completes patient enrolment for phase I/II trial of cancer therapy ELC-100
Repare Therapeutics reports positive safety and tolerability data from Phase 1 MYTHIC trial